Literature DB >> 31098660

[Advantages of a designated IVI center for a German university eye hospital].

Alaa Din Abdin1, Shady Suffo2, Mona Bischoff-Jung2, Loay Daas2, Max Pattmöller2, Berthold Seitz2.   

Abstract

BACKGROUND: Since 2016, a designated center for the intravitreal injections (IVI) has been established at the department of ophthalmology. Many aims had supported the project of moving IVIs from the main operations theater. This study aimed to assess the practicality and feasibility of such a move.
METHODS: In this IVI center, only patients with macular diseases are treated. The premises are arranged directly next to each other. The standardized treatment process starts with registration. Parallel to the formalities, a refraction test is carried out. If necessary optical coherence tomography (OCT) is carried out and then a full eye examination is performed by a doctor. Afterwards, a specialist/consultant decides on the subsequent treatment strategy. The injection takes place in an adjacent standard designated operating room. Patients are handed the computer-generated discharge letters immediately after the procedure and further appointments are booked on discharge.
RESULTS: Despite a 25% increase in the number of IVIs to more than 4000 IVIs per year over the last 2 years, advantages from the establishment of the designated center have resulted as follows: optimal care through precise treatment systems and shorter waiting times. From July to August 2018, 85% of voluntarily participating patients pressed the green or light green smiley face on the "HappyOrNot smiley terminal system". Pressure is taken off the regular outpatient macular consultation service, fixed and direct contact person, pressure is taken off the main operations theater with a significant increase in the diagnosis-related groups (DRG) revenues of 900,000 € and easily accessible database for statistical and scientific purposes.
CONCLUSION: The designated center proved to be an extremely useful and beneficial one-stop center (IVI carrousel) for patients requiring IVI and macular consultations. It significantly released the pressure on both the outpatient department and the outpatient operation center.

Entities:  

Keywords:  Intravitreal injections; Macular diseases; Outpatient clinic

Mesh:

Year:  2020        PMID: 31098660     DOI: 10.1007/s00347-019-0911-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  8 in total

1.  [Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2005-05       Impact factor: 0.700

2.  [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: endophthalmitis prophylaxis intravitreal operative medications input (IVOM) (July 2013)].

Authors:  H Hoerauf; F G Holz; A Kramer; N Feltgen; T Krohne; W Behrens-Baumann
Journal:  Klin Monbl Augenheilkd       Date:  2013-11-15       Impact factor: 0.700

3.  [Academic teaching at the department of ophthalmology of the University Clinic of Saarland (UKS) : The Homburg "Ophthalmo-Week"].

Authors:  B Käsmann-Kellner; B Seitz
Journal:  Ophthalmologe       Date:  2015-06       Impact factor: 1.059

4.  [The Homburger Curriculum as a model for medical resident education for ophthalmologists at Saarland University Medical Center].

Authors:  S Goebels; A Viestenz; B Seitz
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

5.  [Establishment of a PJ Faculty at the Medical Faculty of Saarland University UdS : "Docendo discimus", "Transparency and communication"].

Authors:  B Seitz; N Graf; M Menger; D Monz; B Käsmann-Kellner
Journal:  Ophthalmologe       Date:  2019-01       Impact factor: 1.059

6.  Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.

Authors:  Alaa Din Abdin; Shady Suffo; Fatima Asi; Achim Langenbucher; Berthold Seitz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-29       Impact factor: 3.117

7.  [Per aspera ad astra: implementation of electronic patient records in a university eye hospital : Experience with FIDUS in the Clinic for Ophthalmology at the Saarland University Medical Center UKS].

Authors:  C Spira-Eppig; T Eppig; M Bischof; G Schießl; G Milioti; B Käsmann-Kellner; H Carstensen; B Schick; B Seitz
Journal:  Ophthalmologe       Date:  2018-10       Impact factor: 1.059

8.  [Work in progress: adaptation of electronic medical records to the requirements of a university eye clinic : Individual extensions of the software "FIDUS" at the Department of Ophthalmology of the Saarland University Medical Center UKS].

Authors:  C Spira-Eppig; T Eppig; M Bischof; G Schießl; G Milioti; B Käsmann-Kellner; H Carstensen; B Schick; B Seitz
Journal:  Ophthalmologe       Date:  2019-11       Impact factor: 1.059

  8 in total
  6 in total

1.  The Impact of the First COVID-19 Lockdown Period on the Inpatient and Outpatient Volume of a University Based Tertiary Referral Center with Corneal Subspecialization in Germany.

Authors:  Nadir Maiassi; Kassandra Xanthopoulou; Ursula Löw; Berthold Seitz
Journal:  Clin Ophthalmol       Date:  2022-06-09

2.  First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.

Authors:  Alaa Din Abdin; Wissam Aljundi; Khalil El Jawhari; Shady Suffo; Isabel Weinstein; Berthold Seitz
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

3.  [Employee survey after introduction of the FIDUS electronic patient file at the Saarland University Eye Hospital].

Authors:  Amine Maamri; Fabian N Fries; Corinna Spira-Eppig; Timo Eppig; Berthold Seitz
Journal:  Ophthalmologe       Date:  2021-10-27       Impact factor: 1.174

4.  Recurrent fungal endophthalmitis after intravitreal injections of bevacizumab.

Authors:  Alaa Din Abdin; Shady Suffo; Dina Alnaggar; Loay Daas; Berthold Seitz
Journal:  Am J Ophthalmol Case Rep       Date:  2020-01-07

5.  Intravitreal Injection for Diabetic Macular Edema as Adjunctive Therapy for Proliferative Diabetic Retinopathy: A Retrospective Study.

Authors:  Wissam Aljundi; Shady Suffo; Cristian Munteanu; Achim Langenbucher; Berthold Seitz; Alaa Din Abdin
Journal:  Clin Ophthalmol       Date:  2022-01-14

6.  Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration.

Authors:  Alaa Din Abdin; Asem Mohamed; Cristian Munteanu; Isabel Weinstein; Achim Langenbucher; Berthold Seitz; Shady Suffo
Journal:  Int J Retina Vitreous       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.